The science
Kisspeptin research: the mechanism and the human trials, study by study
From the genetics that revealed the pathway to the 2025 intranasal data — each finding attributed to its source.
Before the details
Kisspeptin research has a clear arc. First came the genetics: in 2003, people born with a broken version of the kisspeptin receptor failed to go through puberty, which told scientists this molecule was essential for reproduction. Then came the lab work showing exactly how it fires the GnRH neurons. Then came the human trials — giving kisspeptin to healthy volunteers, to women with missing periods, and to IVF patients — to see what it does to the reproductive hormones LH and FSH. The answers were consistent: kisspeptin reliably switches the system on. The catch, found again and again, is that giving it continuously wears the receptor out within days. The studies below walk through that arc in order, each tied to its published source.
The genetics that revealed the pathway
The pathway announced itself through human genetics. Loss-of-function mutations in GPR54 (KISS1R) caused autosomal-recessive idiopathic hypogonadotropic hypogonadism with failure of puberty in affected kindreds, and Gpr54-knockout mice reproduced the phenotype — together establishing kisspeptin-GPR54 signaling as essential for reproductive maturation and identifying the receptor as a gatekeeper of puberty [1]. A complementary line of work confirmed that kisspeptin acts directly on GnRH neurons through GPR54: the receptor's transcripts co-localize with GnRH neurons, kisspeptin fails to stimulate LH or FSH in Gpr54-knockout mice, and central administration in sheep triggers GnRH release into cerebrospinal fluid with a parallel rise in serum LH [13]. Early human neuroendocrine work then showed that acute intravenous kisspeptin in healthy male volunteers potently increased plasma LH and significantly raised FSH and testosterone, with inactivating GPR54 mutations causing normosmic hypogonadotropic hypogonadism [16].
How kisspeptin excites the GnRH neuron
At the cellular level, kisspeptin (100 nM) depolarized GnRH neurons by 6 +/- 1 mV and increased firing rate by 87 +/- 4% in about 75% of adult GnRH neurons, through a phospholipase C / IP3 / calcium cascade that closes potassium channels and opens non-selective cation channels [2]. That ion-channel mechanism is the physical basis for everything downstream: a kisspeptin signal becomes a GnRH pulse, which becomes an LH and FSH pulse from the pituitary. The arcuate KNDy neurons — co-expressing kisspeptin, neurokinin B, and dynorphin — are the proposed pulse generator: in ewes, NK3-receptor signaling initiates synchronized KNDy activity, kappa-opioid (dynorphin) signaling terminates it, and kisspeptin relays the output to GnRH neurons [8]. A broader review consolidated this KNDy model as the mammalian GnRH pulse generator controlling reproduction [9].
Kisspeptin-10
Kisspeptin-10 (KP-10) is the short C-terminal decapeptide, and it is a potent LH stimulator in humans. In healthy men, an intravenous KP-10 bolus produced maximal LH stimulation at 1 ug/kg (LH 4.1 to 12.4 IU/L at 30 minutes); a continuous infusion at 1.5 ug/kg/h raised mean LH from 5.2 to 14.1 IU/L and increased LH pulse frequency from 0.7 to 1.0 pulses/h, while a higher 4 ug/kg/h infusion raised serum testosterone from 16.6 to 24.0 nmol/L [3]. KP-10's practical drawback is duration: it is cleared by plasma peptidases within minutes, so its functional half-life is short — a property the dosage page covers against KP-54.
Kisspeptin-54
Kisspeptin-54 (KP-54, originally metastin) is the longer isoform with a substantially longer duration of action, and it carries most of the clinical-application research. In women with hypothalamic amenorrhea, continuous intravenous KP-54 (0.01-1.00 nmol/kg/h) restored pulsatile LH secretion: LH pulses rose from 1.6 to 5.0 per 8 hours (~3-fold) and pulse secretory mass from 3.92 to 23.44 IU/L (~6-fold) versus vehicle — though the highest dose produced tachyphylaxis over the infusion [4]. As an IVF oocyte-maturation trigger in 60 women at high OHSS risk, subcutaneous KP-54 (3.2-12.8 nmol/kg) matured oocytes in 95% of women with no case of moderate, severe, or critical OHSS, and the highest live-birth rate (62%) followed the 9.6 nmol/kg dose [5].
The 2025 intranasal data and the clinical landscape
Delivery is moving beyond the needle. In 2025, intranasal kisspeptin-54 (primary dose 12.8 nmol/kg) rapidly stimulated LH release in healthy men (+4.4 IU/L), healthy women (+1.4 IU/L), and women with hypothalamic amenorrhea (+4.4 IU/L) without adverse events, with the nasal-spray formulation stable for up to 60 days at 4 degrees C — the first clinical demonstration of effective non-invasive intranasal delivery [6]. Zooming out, a systematic review (databases searched through February 2023) identified 29 interventional clinical trials studying kisspeptin across secondary amenorrhea, puberty regulation, ovarian function, trophoblast invasion, fertility regulation, parturition, and lactation, noting considerably fewer side effects than comparators — while confirming that no kisspeptin product is regulatory-approved [7]. Reviews have also extended the system beyond reproduction: KNDy/kisspeptin signaling has been linked to thermoregulation and menopausal hot flushes [11], and circulating placental kisspeptin has been proposed as a candidate biomarker for pregnancy complications [12]. The KISS1R system's control of the full HPG axis, including loss- and gain-of-function effects on puberty, is summarized in a dedicated review [10].
From metastasis suppressor to master switch
The pathway's history is unusual. KISS1 was first described in 1996 not as a reproductive gene at all but as a metastasis-suppressor gene in human melanoma, which is why kisspeptin-54 still carries the older name metastin. Its receptor — then an orphan GPCR called GPR54 — was matched to kisspeptin around 2001. The reframing came in 2003, when the puberty genetics landed: loss-of-function GPR54 mutations were shown to cause hypogonadotropic hypogonadism and failure of puberty, and the molecule was reinterpreted as the master upstream switch of the reproductive axis [1]. The mechanistic confirmation followed, with kisspeptin shown to act directly on GnRH neurons through GPR54 across mouse and sheep models [13]. That two-stage history — a cancer gene that turned out to govern reproduction — is why the literature spans oncology, developmental endocrinology, and fertility, and why the receptor, not the peptide, is treated as the control point.
The open questions the literature flags
The record is honest about its limits. Most controlled human data come from a small number of research centers, notably Imperial College London, so large independent multi-center replication is still limited [7]. The KISS1 system is context-dependent in cancer — anti-metastatic in most solid tumors but potentially pro-tumorigenic in some liver and breast settings — so it cannot be read as uniformly tumor-suppressive. Appetite effects are unsettled: rodent work suggested kisspeptin can suppress food intake, but a human study in women with overweight or obesity found no effect on hunger or food intake. And a rodent atherosclerosis study reported that kisspeptin-10 accelerated plaque progression, an effect reversed by a GPR54 antagonist — a cardiovascular signal not characterized in humans [15]. These are surfaced here, not resolved; they are exactly the kind of open question a study-attributed digest should mark rather than smooth over.